Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -55.47
- Piotroski Score 3.00
- Grade Hold
- Symbol (TTOO)
- Company T2 Biosystems, Inc.
- Price $0.51
- Changes Percentage (2.66%)
- Change $0.01
- Day Low $0.51
- Day High $0.55
- Year High $8.38
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/13/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $109.92
- Trailing P/E Ratio 0.04
- Forward P/E Ratio 0.04
- P/E Growth 0.04
- Net Income $-50,077,000
Income Statement
Quarterly
Annual
Latest News of TTOO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Pete Hegseth hits back at accusations his tattoos are white...
Trump's nominee for Secretary of Defense, Pete Hegseth, defends his tattoos against white supremacy claims, denouncing it as anti-Christian bias. Hegseth vows to oppose woke initiatives in the Departm...
By New York Post | 2 days ago -
The tattooed Secretary of Defense: Here is all of Pete Hegseth's ink,...
President-Elect Donald Trump's Secretary of Defense nominee Pete Hegseth is a decorated war veteran with tattoos. Hegseth, a double Ivy Leaguer, has controversial ink including a Jerusalem Cross and "...
By New York Post | 5 days ago -
Chicago area veteran asks doctors to save special tattoo during heart transplant
After a 21-year military career, Sgt. First Class Louis B. Smith Jr. faced heart failure. A successful transplant preserved his special tattoo, a tribute to his late father and a symbol of resilience....
By CBS News | 6 days ago
